PANAMA was the first randomized study evaluating the addition of an anti-EGFR antibody to maintenance therapy with fluorouracil and folic acid (FU/FA) in patients with previously untreated metastatic colorectal cancer (mCRC) with a non-mutated (wt − wild-type) RAS oncogene. The results suggest that upon achieving disease control after initial treatment with FOLFOX + panitumumab, the combination of panitumumab with FU/FA might be the most suitable for maintenance therapy.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
